Delta dawns on acquisition radar for Astrea Bioseparations
Cambridge-based Astrea Bioseparations, which provides bioseparation and purification technologies, has acquired Delta Precision Ltd, a UK manufacturer of advanced chromatography columns for the biotech and pharma industries. No figures have been disclosed.
The strategic acquisition follows a long-standing relationship of almost a decade. It will allow Astrea Bio to expand its product offering to include a full range of high-performance chromatography columns for biomanufacturing, complementing and strengthening the company’s existing portfolio of bioprocessing resins, reusable columns, and prepacked single-use columns.
Gloucestershire company Delta Precision’s products are used in a variety of applications including protein purification, vaccine production, and drug development.
Astrea is a subsidiary of Gamma Biosciences, headquartered in Menlo Park in California. Gamma supplies resins for more than 21 FDA and EMA approved manufacturing processes.
Anchored at Horizon Park in Comberton, near Cambridge, Astrea has had an interesting journey. In 1987, a Cambridge University working group spun out under the name Affinity Chromatography Limited.
Through the years, the name and owner changed, including time as Prometic Bioseparations before being sold in late 2019 and subsequently rebranding to Astrea Bioseparations.
Terry Pizzie, CEO of Astrea Bio, said: “The acquisition of Delta is another step forward in Astrea Bio’s rapid expansion to support the biopharmaceutical manufacturing field.
“This is a highly strategic move for us, allowing us to offer a full range of industry-leading purification and separation tools.”
Geoff Parnell, co-founder and managing director at Delta Precision, added: “We look forward to joining the Astrea Bio family, further cementing the long-standing relationship between the two companies.
“We are confident that our expertise in column manufacturing will complement and accelerate the Astrea Bio business and customer reach.”